How Rheumatology Clinics Are Reclaiming Denied Biologic Revenue Through Free AI-Powered Appeals
Rheumatology practices face an existential financial challenge in 2025: escalating denial rates for high-value biologic medications that represent the cornerstone of modern inflammatory disease treatment. With biologic therapies accounting for 60-70% of rheumatology practice revenue and denial rates climbing to 25-35% for specialty medications, clinics are hemorrhaging millions in recoverable